CA3094307A1 - Methods for treating melanoma - Google Patents

Methods for treating melanoma Download PDF

Info

Publication number
CA3094307A1
CA3094307A1 CA3094307A CA3094307A CA3094307A1 CA 3094307 A1 CA3094307 A1 CA 3094307A1 CA 3094307 A CA3094307 A CA 3094307A CA 3094307 A CA3094307 A CA 3094307A CA 3094307 A1 CA3094307 A1 CA 3094307A1
Authority
CA
Canada
Prior art keywords
melanoma
tumor
dapansutrile
cells
diet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3094307A
Other languages
English (en)
French (fr)
Inventor
Carlo MARCHETTI
Charles A. Dinarello
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Olatec Therapeutics Inc
Original Assignee
Olatec Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Olatec Therapeutics Inc filed Critical Olatec Therapeutics Inc
Publication of CA3094307A1 publication Critical patent/CA3094307A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3094307A 2018-03-21 2019-03-18 Methods for treating melanoma Pending CA3094307A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862645999P 2018-03-21 2018-03-21
US62/645,999 2018-03-21
PCT/US2019/022770 WO2019182981A1 (en) 2018-03-21 2019-03-18 Methods for treating melanoma

Publications (1)

Publication Number Publication Date
CA3094307A1 true CA3094307A1 (en) 2019-09-26

Family

ID=67987925

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3094307A Pending CA3094307A1 (en) 2018-03-21 2019-03-18 Methods for treating melanoma

Country Status (7)

Country Link
US (1) US11857529B2 (cg-RX-API-DMAC7.html)
EP (1) EP3768384B1 (cg-RX-API-DMAC7.html)
JP (1) JP7229565B2 (cg-RX-API-DMAC7.html)
CN (1) CN111867678B (cg-RX-API-DMAC7.html)
CA (1) CA3094307A1 (cg-RX-API-DMAC7.html)
MX (1) MX2020009552A (cg-RX-API-DMAC7.html)
WO (1) WO2019182981A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12121565B2 (en) * 2019-09-13 2024-10-22 Duke University Methods of treatment of specific cancers with NLRP3 inhibitors and anti-PD1/PD-L1 antibodies
EP4045009A4 (en) * 2019-10-14 2023-11-01 Olatec Therapeutics LLC METHOD FOR TREATING BREAST CANCER
EP4387729A4 (en) * 2021-08-19 2025-07-09 Olatec Therapeutics Inc METHODS OF TREATMENT OF PARKINSON'S DISEASE
WO2026035767A1 (en) * 2024-08-06 2026-02-12 Olatec Therapeutics, Inc. Methods for treating melanoma metastasis to liver and lungs

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2013006708A (es) * 2010-12-15 2013-09-13 Olatec Ind Llc Composicion de 3-metanosulfonilpropionitrilo para el tratamiento de la inflamacion y el dolor.
CA2875053C (en) * 2012-06-05 2020-07-14 Olatec Industries Llc Pharmaceutical composition for treating inflammation and pain
JP6185575B2 (ja) * 2012-06-05 2017-08-23 オラテック セラピューティクス リミティド ライアビリティ カンパニー 皮膚炎症性疾患の治療方法
JP6929792B2 (ja) * 2015-02-16 2021-09-01 ザ ユニバーシティ オブ クィーンズランド スルホニル尿素及び関連化合物並びにその使用
EP3288980B1 (en) * 2015-04-28 2021-03-10 Bristol-Myers Squibb Company Treatment of pd-l1-positive melanoma using an anti-pd-1 antibody
EP3445761A1 (en) * 2016-04-19 2019-02-27 Innate Tumor Immunity, Inc. Nlrp3 modulators
NL2017267B1 (en) * 2016-07-29 2018-02-01 Aduro Biotech Holdings Europe B V Anti-pd-1 antibodies
ES2970485T3 (es) * 2017-01-06 2024-05-29 Olatec Therapeutics Llc Composición farmacéutica para su uso en el tratamiento de enfermedades cardiovasculares
EP3589370A4 (en) * 2017-01-06 2020-11-18 Olatec Therapeutics LLC MULTIPLE SCLEROSIS TREATMENT METHOD
US20210254056A1 (en) 2017-05-05 2021-08-19 Camp4 Therapeutics Corporation Identification and targeted modulation of gene signaling networks
WO2019152627A1 (en) * 2018-01-31 2019-08-08 Olatec Therapeutics Llc Method for preventing or treating alzheimer's disease

Also Published As

Publication number Publication date
JP2021518374A (ja) 2021-08-02
WO2019182981A1 (en) 2019-09-26
JP7229565B2 (ja) 2023-02-28
CN111867678A (zh) 2020-10-30
EP3768384A4 (en) 2021-11-17
EP3768384B1 (en) 2025-06-25
US20200405681A1 (en) 2020-12-31
EP3768384A1 (en) 2021-01-27
MX2020009552A (es) 2020-10-05
US11857529B2 (en) 2024-01-02
CN111867678B (zh) 2023-04-28

Similar Documents

Publication Publication Date Title
US11857529B2 (en) Methods for treating melanoma
US20130022609A1 (en) Method of treating androgen independent prostate cancer
JP6963545B2 (ja) 癌を治療するための併用療法
JP2020520921A (ja) 癌を処置する併用療法
CN108139403B (zh) 用于组合疗法的患者的选择
US12582628B2 (en) Methods for treating breast cancer
US11517575B2 (en) Use of minaprine to reduce tumor growth
JP2011506436A (ja) 細胞傷害性tリンパ球抗原4(ctla4)に対する抗体と組み合わせられたアルファチモシンペプチドによる黒色腫の処置の方法
KR20090020646A (ko) 4기 악성 흑색종의 치료를 위한 약제의 제조를 위한 티모신알파 1의 용도
EP3664786B1 (en) Method for treating schnitzler's syndrome
US20240417812A1 (en) Methods for treating solid cancer patients with clonal hematopoiesis of indeterminate potential
US20240358669A1 (en) Methods for treating pancreatic cancer
WO2026035767A1 (en) Methods for treating melanoma metastasis to liver and lungs
Arshad 68P Neratinib in combination with fulvestrant and or palbociclib can overcome endocrine resistance in HER2-low/ER+ breast cancer
US20170224683A1 (en) Treatment of melanoma by blocking benzamil sensitive ion channels/exchangers
HK40096805A (en) Selection of patients for combination therapy
WO2025021587A1 (en) Combination of a mps1 inhibitor and immune checkpoint inhibitors, uses and pharmaceutical compositions thereof
KR20200124661A (ko) 종양 성장을 감소시키기 위한 미나프린의 용도

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20231222

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250128

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - SMALL

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250310

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250310

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250310

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250514

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250516

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250722

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250722

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - SMALL

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260309

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260309

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260511

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260511